Inhibikase Therapeutics, Inc. (IKT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 201.54M |
| Enterprise Value | 62.32M |
| P/E Ratio | -5.03 |
| PEG Ratio | -0.04 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 2.72 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -4.56 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -0.37 |
| Return On Equity | -0.43 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -53.29M |
| Net Income | -48.26M |
| Diluted EPS | -0.49 |
| Total Cash | 159.02M |
| Total Cash/Share | 0.91 |
| Total Debt | 0 |
| Total Debt/Equity | 0 |
| Current Ratio | 15.82 |
| Book Value Per Share | 0.88 |
| 52-Week Change | 35.8 |
| 52-Week High | 2.53 |
| 52-Week Low | 1.33 |
| Moving Average 50 Days | 2.13 |
| Moving Average 200 Days | 1.83 |
| Average Volume | 789,893 |
| Shares Outstanding | 132.03M |
| % Held by Institutions | 115.95 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
| Last Split Date | June 30, 2023 |